- Design and Synthesis of Novel Spiro Derivatives as Potent and Reversible Monoacylglycerol Lipase (MAGL) Inhibitors: Bioisosteric Transformation from 3-Oxo-3,4-dihydro-2 H-benzo[ b][1,4]oxazin-6-yl Moiety
-
The therapeutic potential of monoacylglycerol lipase (MAGL) inhibitors in central nervous system-related diseases has attracted attention worldwide. However, the availability of reversible-type inhibitor is still limited to clarify the pharmacological eff
- Ikeda, Shuhei,Sugiyama, Hideyuki,Tokuhara, Hidekazu,Murakami, Masataka,Nakamura, Minoru,Oguro, Yuya,Aida, Jumpei,Morishita, Nao,Sogabe, Satoshi,Dougan, Douglas R.,Gay, Sean C.,Qin, Ling,Arimura, Naoto,Takahashi, Yasuko,Sasaki, Masako,Kamada, Yusuke,Aoyama, Kazunobu,Kimoto, Kouya,Kamata, Makoto
-
p. 11014 - 11044
(2021/08/24)
-
- TISSUE FACTOR PRODUCTION INHIBITOR
-
A medicament which has an activity of inhibiting production of tissue factor and comprises an LXR ligand as an active ingredient; and a medicament for treatment and/or prophylaxis of vascular restenosis following angioplasty, endarterectomy, percutaneous transluminal coronary angioplasty (PTCA) or stent implantation, or treatment and/or prophylaxis of blood coagulation diseases, diseases induced by platelet aggregation including stable or unstable angina pectoris, cardiovascular and cerebrovascular diseases including thromboembolism formation diseases accompanying diabetes, rethrombosis following thrombolysis, cerebral ischemic attack, infarction, stroke, ischemia-derived dementia, peripheral artery disease, thromboembolism formation diseases during use of an aorta-coronary artery bypass, glomerulosclerosis, renal embolism, tumor or cancer metastasis, which comprises an LXR ligand as an active ingredient.
- -
-
Page/Page column 108-109
(2010/11/26)
-